![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.25 | 1.20 | 1.30 | 1.25 | 1.25 | 1.25 | 134,269 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.57 | 1.69M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/6/2024 17:07 | 'The project is valued at £161,580 and is anticipated to be completed over the next five months. The project, and associated contract award, is one of the two referred to in the Company's trading update on 3 May 2024' So, already priced in to the share price. | ![]() davevt | |
07/6/2024 10:02 | 7 June 2024 Physiomics plc Contract Award Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a significant contract by a new UK-based biotech client. This client sits at the forefront of AI-driven design and development of novel therapies across various therapeutic areas. The project involves the use of our proprietary Virtual Tumour technology to help guide the Phase 1b/2 dosing regimens for one of their oncology assets and benchmark it against the competition. The project is valued at £161,580 and is anticipated to be completed over the next five months. The project, and associated contract award, is one of the two referred to in the Company's trading update on 3 May 2024. Dr Peter Sargent, CEO, commented: "We at Physiomics are very excited about starting our first project with this exciting new client and we look forward to working with their team over the coming months and hopefully on further programmes in the future". | ![]() thiopia | |
30/5/2024 00:31 | Previously:- Congratulations to our client Numab Therapeutics AG on this fantastic achievement! Great to have worked with Numab on the NM26 programme “We have worked with Physiomics on a PK/PD modelling project for our molecule NM26-2198, intended for use in patients with inflammatory disease. The work has been highly productive, valuable and enjoyable. The Physiomics team are knowledgeable, helpful and dedicated to provide the expertise required to bring the project to fruition. Based on this excellent collaboration we will certainly be working with Physiomics again.” Daniel Snell, VP Translational Science Now:- Numab is thrilled to announce that Johnson & Johnson has entered into a definitive agreement to acquire Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab that holds the rights to NM26. NM26 is an investigational first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis, discovered and engineered through Numab’s proprietary MATCH™ technology platform. Johnson & Johnson will pay a purchase price of $1.25 billion and will gain the full rights to develop, manufacture and commercialize NM26 globally for atopic dermatitis and follow-on indications. This acquisition further validates our discovery and engineering platform and its potential to bring novel multi-specific antibodies to underserved patient populations. | ![]() thiopia | |
25/5/2024 20:00 | It just takes time. The Bletchley Declaration will be most apparent re Physiomics future. Wheels within wheels but I have a good holding here and content to see the longer game play out. | ![]() criticalthinker1 | |
25/4/2024 00:33 | Critical, the last time you posted, the price was higher than this, so what do you mean nice and steady? | ![]() davevt | |
23/4/2024 10:34 | Spot on CT1 | ![]() ant15 | |
23/4/2024 10:02 | Nice and steady 👌 | ![]() criticalthinker1 | |
19/3/2024 20:06 | Just because people may get excited and buy shares and The price goes up doesn't mean revenues are linked to mcap, because this share is currently sitting lower, with a lower mcap than previously, AFTER releasing news of new contracts and revenues. So that just blew your theory didn't it.. | ![]() davevt | |
19/3/2024 13:15 | It's not just good news, it's great news. Existing big pharma client putting more business the company's way. More of that please! Market makers persisting with the daft spread, buys actually above 1.3p. | ![]() le mass du pap | |
19/3/2024 12:54 | It's new business, new money, new income and a significant proportion of the company's entire market capitalisation, so of course it's significant. No doubt if they'd lost the client you'd be saying it's significant. A quick look at your posts shows you've been negative on everything PYC related for some time, and only PYC. So you've clearly got something against this company in particular and therefore your comments cannot be taken seriously. There's one on every board. | ![]() simonsmithiv | |
19/3/2024 12:33 | Comparison to mcap is irrelevant. They aren't even related metrics. And it's an existing customer. You're meant to keep existing customers. You have a very low bar if a repeat customer using the services you're meant to do is 'good news'. | ![]() davevt | |
18/3/2024 16:12 | Because it's a new contract and it's £178k (not 150k). And because it's >10% of the mcap over just 6 months, >20% yearly. So it is significant, even though it's 'what they're meant to do'. It's very good news, with plenty more to come by the sounds of it. | ![]() simonsmithiv | |
18/3/2024 15:57 | Because it's only 150k for 6 months work. I don't even know why pyc release and rns for doing what they are meant to do. | ![]() davevt | |
18/3/2024 14:23 | Good news this am with a decent sized contract for such a small market cap, surprised it hasn't kicked on yet. The investor presentation sounded solid, with a focus on expanding income streams, securing new clients and contracts and very much pushing on from here. CEO sounded positive and hinted at more news to come with the pipeline for this year up significantly. Therefore I can only assume we have seen the lows? | ![]() le mass du pap | |
18/3/2024 10:20 | Rising on contract award from oversold RSI and tight sma's at the thin end of the squeeze. Investor presentation later today. free stock charts from uk.advfn.com | ![]() simonsmithiv | |
18/3/2024 09:00 | Mcap only £1.6m | ![]() simonsmithiv | |
18/3/2024 08:24 | And another one. Quite interesting this one! | ![]() criticalthinker1 | |
18/3/2024 08:14 | That's better, over 10% of the mcap in one contract award. | ![]() simonsmithiv | |
07/3/2024 07:59 | There's start ups on Dragons Den making more than this. | ![]() simonsmithiv | |
07/3/2024 07:28 | “The Directors believe the Company will continue to trade in line with market expectations.“ So after all that waffle and more than 2 decades of constant loss making, they are expecting more of the same. Exciting times huh. | terminator101 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions